Your institution may have access to this item. Find your institution then sign in to continue.
Title
Cost-effectiveness of full medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes.
Authors
Rosen, Allison B; Hamel, Mary Beth; Weinstein, Milton C; Cutler, David M; Fendrick, A Mark; Vijan, Sandeep
Abstract
Angiotensin-converting enzyme (ACE) inhibitors slow renal disease progression and reduce cardiac morbidity and mortality in patients with diabetes. Patients' out-of-pocket costs pose a barrier to using this effective therapy.
Publication
Annals of internal medicine, 2005, Vol 143, Issue 2, p89